RO 20-1724 Chemical Properties

Melting point:

125-127°

Boiling point:

483.8±25.0 °C(Predicted)

Density 

1.099±0.06 g/cm3(Predicted)

storage temp. 

room temp

solubility 

ethanol: 7 mg/mL

form 

solid

pka

14.54±0.40(Predicted)

color 

White

biological source

synthetic (organic)

Stability:

Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 6 months.

CAS DataBase Reference

29925-17-5(CAS DataBase Reference)

Safety Information

Hazard Codes 

Xi

Risk Statements 

36/37/38

Safety Statements 

26-36

WGK Germany 

3

MSDS

• Language:English Provider:SigmaAldrich

RO 20-1724 Usage And Synthesis

Description

RO 20-1724 (29925-17-5) is a selective inhibitor of cAMP-specific phosphodiesterase (PDE4), IC50 = 0.2 μM. Displays anti-inflammatory activity. Cell permeable

Uses

Ro 20-1724 is a cell-permeable, cAMP-specific phosphodiesterase type IV (PDE4) inhibitor (IC50 = 2 μM). It weakly inhibits PDE3 with a Ki value greater than 25 μM. Ro 20-1724 inhibits the release of cytokines and other inflammatory signals as well as prevents the development of reactive oxygen species. It is often used to study cAMP-related functions in vascular cells.

Uses

Ro 20-1724 Is an inhibitor of phosphodiesterase-4, and also very effective for patients with plaque psoriasis. Selective inhibitor of cAMP-specific phosphodiesterase. Selective PDE4 inhibitor.

Definition

ChEBI: 4-[(3-butoxy-4-methoxyphenyl)methyl]-2-imidazolidinone is a member of methoxybenzenes.

Biological Activity

Widely used inhibitor of cyclic nucleotide phosphodiesterase, selective for PDE4 (IC 50 = 2.0 μ M). Also available as part of the Phosphodiesterase Inhibitor Tocriset™ .

Biochem/physiol Actions

Inhibitor of cAMP phosphodiesterase. IC50 33 μM in vascular smooth muscle of the aorta.

storage

Store at RT

References

[1] S H SODERLING J A B S J Bayuga. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase.[J]. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95 15: 8991-8996. DOI:10.1073/pnas.95.15.8991
[2] C D NICHOLSON  M S  R A Challiss. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.[J]. Trends in pharmacological sciences, 1991, 12 1: 19-27. DOI:10.1016/0165-6147(91)90484-a

RO 20-1724(29925-17-5)Related Product Information

• ZARDAVERINE
• S- (+)-Rolipram
• ETAZOLATE
• BRL 50481
• Vinpocetine
• ZAPRINAST
• ROLIPRAM
• Cilostazol
• (4S)-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]PYRROLIDIN-2-ONE
• CILOSTAMIDE
• EHNA HYDROCHLORIDE
• 4-[[3,4-(METHYLENEDIOXY)BENZYL]AMINO]-6-CHLOROQUINAZOLINE
• 3-ETHOXY-4-METHOXYPHENETHYLAMINE
• 3-ETHOXYPHENETHYLAMINE
• 3-(3-METHOXY-PHENYL)-PROPYLAMINE
• RO 20-1724
• 2-Imidazolidinone, 4-((3-(cyclopentyloxy)-4-methoxyphenyl)methyl)-
• AKOS BB-3072